Inari Medical, Inc.

DB:IM7 Stock Report

Market Cap: €2.9b

Inari Medical Valuation

Is IM7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IM7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IM7 (€48.8) is trading above our estimate of fair value (€20.87)

Significantly Below Fair Value: IM7 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IM7?

Key metric: As IM7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IM7. This is calculated by dividing IM7's market cap by their current revenue.
What is IM7's PS Ratio?
PS Ratio5.3x
SalesUS$574.50m
Market CapUS$2.99b

Price to Sales Ratio vs Peers

How does IM7's PS Ratio compare to its peers?

The above table shows the PS ratio for IM7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.7x
AFX Carl Zeiss Meditec
2x6.4%€4.1b
EUZ Eckert & Ziegler
3.3x5.4%€918.5m
DRW3 Drägerwerk KGaA
0.3x3.8%€801.6m
SBS Stratec
1.4x7.4%€361.6m
IM7 Inari Medical
5.3x14.3%€3.0b

Price-To-Sales vs Peers: IM7 is expensive based on its Price-To-Sales Ratio (5.3x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does IM7's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.8%US$822.20m
PHH2 Paul Hartmann
0.3xn/aUS$801.91m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
IM7 5.3xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IM7 is expensive based on its Price-To-Sales Ratio (5.3x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is IM7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IM7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ratio7.1x

Price-To-Sales vs Fair Ratio: IM7 is good value based on its Price-To-Sales Ratio (5.3x) compared to the estimated Fair Price-To-Sales Ratio (7.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IM7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€48.80
€63.90
+30.9%
15.5%€82.53€47.98n/a14
Dec ’25€47.20
€60.32
+27.8%
16.2%€81.94€47.64n/a13
Nov ’25€44.20
€58.26
+31.8%
16.9%€79.53€44.39n/a13
Oct ’25€36.40
€57.03
+56.7%
17.5%€77.37€42.29n/a13
Sep ’25€38.80
€60.53
+56.0%
15.0%€78.77€45.80n/a11
Aug ’25€48.40
€60.86
+25.7%
15.7%€79.42€46.18n/a10
Jul ’25€44.00
€59.83
+36.0%
20.3%€80.28€43.87n/a11
Jun ’25€45.60
€60.23
+32.1%
21.1%€80.44€43.96n/a10
May ’25€35.00
€60.23
+72.1%
21.1%€80.44€43.96n/a10
Apr ’25€44.40
€68.20
+53.6%
17.9%€92.54€48.12n/a10
Mar ’25€42.60
€68.84
+61.6%
16.0%€92.28€50.75n/a10
Feb ’25€52.00
€74.53
+43.3%
13.8%€92.12€58.04n/a10
Jan ’25€58.00
€75.14
+29.5%
12.3%€90.89€61.81€49.609
Dec ’24€54.00
€74.40
+37.8%
16.0%€93.26€60.62€47.209
Nov ’24€56.50
€80.44
+42.4%
13.3%€94.63€56.78€44.208
Oct ’24n/a
€78.90
0%
11.8%€91.39€59.40€36.409
Sep ’24n/a
€78.90
0%
11.8%€91.39€59.40€38.809
Aug ’24n/a
€77.77
0%
12.8%€93.74€58.03€48.409
Jul ’24n/a
€82.54
0%
11.5%€97.65€65.10€44.008
Jun ’24n/a
€82.54
0%
11.5%€97.65€65.10€45.608
May ’24n/a
€83.94
0%
13.2%€96.06€64.04€35.008
Apr ’24n/a
€84.35
0%
13.7%€96.80€62.69€44.408
Mar ’24n/a
€86.13
0%
14.6%€99.25€61.44€42.608
Feb ’24n/a
€83.37
0%
15.2%€96.59€59.79€52.008
Jan ’24n/a
€86.96
0%
11.8%€98.89€70.64€58.009

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 09:02
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inari Medical, Inc. is covered by 21 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Nisala WeerasuriyaBerenberg